Summary
- Accel is in advanced discussions to lead a funding round of $30 million to $40 million in Truemeds, an Indian online pharmacy
- Talks revolve around a proposed valuation of about $330 million for the startup
- Truemeds aims to provide more affordable generic alternatives to costly branded medications by disrupting the supply chain
- Potential funding would more than double Truemeds’ valuation, which was $132 million in the previous round